Lannett Company Inc and Spectrum Pharmaceuticals Inc have announced an agreement for the manufacturing, supply, distribution and marketing of Ciprofloxacin tablets. Ciprofloxacin is the chemical ingredient in Cipro, a drug marketed by Bayer Corporation, and is used to treat bacterial infections.
Under the terms of the agreement, Spectrum, through its NeoJB, LLC subsidiary, will provide Ciprofloxacin tablets exclusively for Lannett. Lannett will market and distribute the product exclusively for Spectrum in the United States. Spectrum filed an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration (FDA) in cooperation with their joint venture partner J.B. Chemicals & Pharmaceuticals.
Following approval of the ANDA, Lannett will launch its distribution of the product to its growing base of customers, including wholesale distributors, generic drug distributors, mail-order wholesalers, warehousing chains, retail chains and other pharmaceutical companies. Since Lannett and Spectrum have no control over the FDA review process, they are unable to anticipate whether or when they will be able to begin commercially shipping the product.